Scalise Filippo, Auguadro Carla, Sorropago Giovanni, Sorropago Antonio, Novelli Eugenio, Finizio Marica, Specchia Giuseppe
Department of Interventional Cardiology, Policlinico di Monza, Monza, Italy.
Biostatistic Unit, Policlinico di Monza, Monza, Italy.
J Interv Cardiol. 2016 Aug;29(4):406-13. doi: 10.1111/joic.12314. Epub 2016 Jun 24.
Percutaneous patent foramen ovale (PFO) closure by means of a septal occluder device (SOD) is a well-known therapeutic strategy for the secondary prevention of paradoxical embolic neurological events. The aim of this study was to provide long-term echocardiographic and clinical follow-up data on patients who had undergone percutaneous PFO closure with 2 different SOD.
We selected 2 groups of patients treated with 2 different SOD: Group A: 52 patients with an Amplatzer(®) PFO Occluder and Group B: 49 patients with a Figulla Flex(®) device. All patients underwent follow-up Bubble Test Transthoracic Echocardiography (BTTE) and clinical examination. The results were compared with those recently reported in a group of patients with similar characteristics, but that had been treated conservatively, which acted as a control group.
The mean follow-up after PFO closure was 53 months. The Amplatzer(®) PFO Occluder and the Figulla Flex were used in 52 (51.5%) and 49 (48.5%) of patients, respectively. We found no significant difference in the rate of effective PFO closure between the devices: Amplatzer 91.4%, Figulla 93.9% (P = 0.71). One patient (1.0%) suffered a recurrent neurologic event. BTTE was positive (BTTE+) in 8 patients (8%), 5 with an Amplatzer, and 3 with a Figulla device (P = 0.516). Only 1 patient with BTTE+ had a recurrent TIA (12.5%). No significant relationship was found between device dimensions and BTTE+ (P = 0.062). In the control group (163 patients), the recurrence of neurologic events was 9.2% (15 events), that was significantly higher in respect to the patients who had undergone percutaneous closure of the PFO.
Percutaneous PFO closure was associated with a remarkably low risk of recurrent embolic neurological events, and no long-term device-related major complications. No statistically significant difference emerged between the 2 different SODs regarding BTTE positivity. Long-term follow-up showed that the recurrence of neurological events has been significantly higher in the group treated in a conservative way.
经皮使用间隔封堵器(SOD)关闭卵圆孔未闭(PFO)是预防反常栓塞性神经事件二级预防的一种知名治疗策略。本研究的目的是提供接受两种不同SOD经皮PFO封堵术患者的长期超声心动图和临床随访数据。
我们选择了两组接受两种不同SOD治疗的患者:A组:52例使用Amplatzer(®)PFO封堵器的患者,B组:49例使用Figulla Flex(®)装置的患者。所有患者均接受随访经胸超声心动图气泡试验(BTTE)和临床检查。将结果与最近报道的一组具有相似特征但接受保守治疗的患者(作为对照组)的结果进行比较。
PFO封堵术后的平均随访时间为53个月。Amplatzer(®)PFO封堵器和Figulla Flex分别用于52例(51.5%)和49例(48.5%)患者。我们发现两种装置之间有效PFO封堵率无显著差异:Amplatzer为91.4%,Figulla为93.9%(P = 0.71)。1例患者(1.0%)发生复发性神经事件。8例患者(8%)BTTE呈阳性(BTTE+),5例使用Amplatzer封堵器,3例使用Figulla装置(P = 0.516)。只有1例BTTE+患者发生复发性短暂性脑缺血发作(12.5%)。未发现装置尺寸与BTTE+之间存在显著关系(P = 0.062)。在对照组(163例患者)中,神经事件复发率为9.2%(15例事件),明显高于接受经皮PFO封堵术的患者。
经皮PFO封堵术与复发性栓塞性神经事件的风险极低相关,且无长期与装置相关的主要并发症。两种不同SOD在BTTE阳性方面未出现统计学显著差异。长期随访表明,保守治疗组的神经事件复发率明显更高。